onr:"swepub:oai:DiVA.org:uu-176225"
Search: onr:"swepub:oai:DiVA.org:uu-176225" > Drotrecogin Alfa (A...
- 1 of 1
- Previous record
- Next record
- To hitlist
Drotrecogin Alfa (Activated) in Adults with Septic Shock
- Ranieri, V. Marco (author)
- Thompson, B. Taylor (author)
- Barie, Philip S. (author)
- show more...
- Dhainaut, Jean-Francois (author)
- Douglas, Ivor S. (author)
- Finfer, Simon (author)
- Marshall, John C. (author)
- Rhodes, Andrew (author)
- Artigas, Antonio (author)
- Payen, Didier (author)
- Al-Khalidi, Hussein R. (author)
- Thompson, Vivian (author)
- Janes, Jonathan (author)
- Macias, William L. (author)
- Vangerow, Burkhard (author)
- Williams, Mark D. (author)
- show less...
- (creator_code:org_t)
- 2012
- 2012
- English.
- In: New England Journal of Medicine. - 0028-4793 .- 1533-4406. ; 366:22, s. 2055-2064
- Journal article (peer-reviewed)
Abstract
Subject headings
Close
- BACKGROUND There have been conflicting reports on the efficacy of recombinant human activated protein C, or drotrecogin alfa (activated) (DrotAA), for the treatment of patients with septic shock. METHODS In this randomized, double-blind, placebo-controlled, multicenter trial, we assigned 1697 patients with infection, systemic inflammation, and shock who were receiving fluids and vasopressors above a threshold dose for 4 hours to receive either DrotAA (at a dose of 24 mu g per kilogram of body weight per hour) or placebo for 96 hours. The primary outcome was death from any cause 28 days after randomization. RESULTS At 28 days, 223 of 846 patients (26.4%) in the DrotAA group and 202 of 834 (24.2%) in the placebo group had died (relative risk in the DrotAA group, 1.09; 95% confidence interval [CI], 0.92 to 1.28; P = 0.31). At 90 days, 287 of 842 patients (34.1%) in the DrotAA group and 269 of 822 (32.7%) in the placebo group had died (relative risk, 1.04; 95% CI, 0.90 to 1.19; P = 0.56). Among patients with severe protein C deficiency at baseline, 98 of 342 (28.7%) in the DrotAA group had died at 28 days, as compared with 102 of 331 (30.8%) in the placebo group (risk ratio, 0.93; 95% CI, 0.74 to 1.17; P = 0.54). Similarly, rates of death at 28 and 90 days were not significantly different in other predefined subgroups, including patients at increased risk for death. Serious bleeding during the treatment period occurred in 10 patients in the DrotAA group and 8 in the placebo group (P = 0.81). CONCLUSIONS DrotAA did not significantly reduce mortality at 28 or 90 days, as compared with placebo, in patients with septic shock.
Publication and Content Type
- ref (subject category)
- art (subject category)
Find in a library
- New England Journal of Medicine (Search for host publication in LIBRIS)
To the university's database
- 1 of 1
- Previous record
- Next record
- To hitlist
Find more in SwePub
- By the author/editor
- Ranieri, V. Marc ...
- Thompson, B. Tay ...
- Barie, Philip S.
- Dhainaut, Jean-F ...
- Douglas, Ivor S.
- Finfer, Simon
- show more...
- Gardlund, Bengt
- Marshall, John C ...
- Rhodes, Andrew
- Artigas, Antonio
- Payen, Didier
- Tenhunen, Jyrki
- Al-Khalidi, Huss ...
- Thompson, Vivian
- Janes, Jonathan
- Macias, William ...
- Vangerow, Burkha ...
- Williams, Mark D ...
- show less...
- Articles in the publication
- New England Jour ...
- By the university
- Uppsala University
- Karolinska Institutet
Search outside SwePub
- Extend your search to:
- Google Book Search
- Google Scholar
Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.
- Copyright © LIBRIS - National Library Systems
- LIBRIS.kb.se
